{"id":4766,"date":"2024-10-08T13:32:33","date_gmt":"2024-10-08T11:32:33","guid":{"rendered":"https:\/\/avextra.com\/?p=4766"},"modified":"2024-10-08T13:56:27","modified_gmt":"2024-10-08T11:56:27","slug":"avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial","status":"publish","type":"post","link":"https:\/\/avextra.com\/en\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","title":{"rendered":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial"},"content":{"rendered":"<p><strong>Bensheim, Germany, Oct. 08, 2024<\/strong> \u2013 Avextra AG (\u201cAvextra\u201d or the \u201cCompany\u201d), a leading European manufacturer and developer of Cannabis-based medicines located in Germany, is proud to announce that both the Italian Medicines Agency AIFA and the Italian Ministry of Health have granted formal approval for a multi-centre Phase II study to evaluate safety, and efficacy of an Avextra oral formulation in managing the symptoms of patients suffering from Amyotrophic Lateral Sclerosis (ALS), Alzheimer\u2019s Disease and Parkinson\u2019s Disease. The study, being conducted under the name NEUROBIS, is one of the few randomised, placebo controlled, double-blind trials to be conducted with a Cannabis-based medicine at multiple sites in Italy. A study of this robust scientific nature aligns perfectly with Avextra\u2019s clinical plan.<\/p>\n\n\n\n<p class=\"has-primary-color has-text-color\"><em><strong><a href=\"https:\/\/www.globenewswire.com\/en\/news-release\/2024\/10\/08\/2959537\/0\/en\/Avextra-Announces-the-Approval-of-NEUROBIS-by-the-Italian-Medicines-Agency-A-Phase-II-Clinical-Trial-Using-a-Proprietary-Cannabis-based-Medicine-for-the-Treatment-of-the-Symptoms-o.html\">Read mor<\/a><a href=\"https:\/\/www.globenewswire.com\/en\/news-release\/2024\/10\/08\/2959537\/0\/en\/Avextra-Announces-the-Approval-of-NEUROBIS-by-the-Italian-Medicines-Agency-A-Phase-II-Clinical-Trial-Using-a-Proprietary-Cannabis-based-Medicine-for-the-Treatment-of-the-Symptoms-o.html\" target=\"_blank\" rel=\"noreferrer noopener\">e<\/a><\/strong><\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>Bensheim, Germany, Oct. 08, 2024 \u2014 Avextra AG\u2026<\/p>","protected":false},"author":2,"featured_media":4768,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"einzelbeitrag-ohne-bild","format":"standard","meta":{"inline_featured_image":false,"advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[9],"tags":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v23.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/avextra.com\/en\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra\" \/>\n<meta property=\"og:description\" content=\"Bensheim, Germany, Oct. 08, 2024 \u2014 Avextra AG\u2026\" \/>\n<meta property=\"og:url\" content=\"https:\/\/avextra.com\/en\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Cannabisbasierte Arzneimittel von Avextra\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-08T11:32:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-08T11:56:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Torsten Meyer-Bautor\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Torsten Meyer-Bautor\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\"},\"author\":{\"name\":\"Torsten Meyer-Bautor\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/aa74df4160383edd63d06428edfecd0b\"},\"headline\":\"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial\",\"datePublished\":\"2024-10-08T11:32:33+00:00\",\"dateModified\":\"2024-10-08T11:56:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\"},\"wordCount\":140,\"publisher\":{\"@id\":\"https:\/\/avextra.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\",\"articleSection\":[\"english\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\",\"url\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\",\"name\":\"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra\",\"isPartOf\":{\"@id\":\"https:\/\/avextra.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\",\"datePublished\":\"2024-10-08T11:32:33+00:00\",\"dateModified\":\"2024-10-08T11:56:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage\",\"url\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\",\"contentUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg\",\"width\":1920,\"height\":1284},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/avextra.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/avextra.com\/#website\",\"url\":\"https:\/\/avextra.com\/\",\"name\":\"Cannabisbasierte Arzneimittel von Avextra\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/avextra.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/avextra.com\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/avextra.com\/#organization\",\"name\":\"Avextra Pharma GmbH\",\"url\":\"https:\/\/avextra.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg\",\"contentUrl\":\"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg\",\"caption\":\"Avextra Pharma GmbH\"},\"image\":{\"@id\":\"https:\/\/avextra.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.linkedin.com\/company\/avextra-ag\/\",\"https:\/\/www.xing.com\/pages\/avextra\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/aa74df4160383edd63d06428edfecd0b\",\"name\":\"Torsten Meyer-Bautor\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/avextra.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b9ef8b21e6c420b5e45a3e65c39ed5b9?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b9ef8b21e6c420b5e45a3e65c39ed5b9?s=96&d=mm&r=g\",\"caption\":\"Torsten Meyer-Bautor\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/avextra.com\/en\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","og_locale":"en_US","og_type":"article","og_title":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra","og_description":"Bensheim, Germany, Oct. 08, 2024 \u2014 Avextra AG\u2026","og_url":"https:\/\/avextra.com\/en\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","og_site_name":"Cannabisbasierte Arzneimittel von Avextra","article_published_time":"2024-10-08T11:32:33+00:00","article_modified_time":"2024-10-08T11:56:27+00:00","og_image":[{"width":1920,"height":1284,"url":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","type":"image\/jpeg"}],"author":"Torsten Meyer-Bautor","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Torsten Meyer-Bautor","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#article","isPartOf":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/"},"author":{"name":"Torsten Meyer-Bautor","@id":"https:\/\/avextra.com\/#\/schema\/person\/aa74df4160383edd63d06428edfecd0b"},"headline":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial","datePublished":"2024-10-08T11:32:33+00:00","dateModified":"2024-10-08T11:56:27+00:00","mainEntityOfPage":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/"},"wordCount":140,"publisher":{"@id":"https:\/\/avextra.com\/#organization"},"image":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","articleSection":["english"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","url":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/","name":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial - Cannabisbasierte Arzneimittel von Avextra","isPartOf":{"@id":"https:\/\/avextra.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage"},"image":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","datePublished":"2024-10-08T11:32:33+00:00","dateModified":"2024-10-08T11:56:27+00:00","breadcrumb":{"@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#primaryimage","url":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","contentUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008.jpg","width":1920,"height":1284},{"@type":"BreadcrumbList","@id":"https:\/\/avextra.com\/2024\/10\/avextra-announces-the-approval-of-neurobis-by-the-italian-medicines-agency-a-phase-ii-clinical-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/avextra.com\/"},{"@type":"ListItem","position":2,"name":"Avextra Announces the Approval of NEUROBIS by the Italian Medicines Agency: A Phase II Clinical Trial"}]},{"@type":"WebSite","@id":"https:\/\/avextra.com\/#website","url":"https:\/\/avextra.com\/","name":"Cannabisbasierte Arzneimittel von Avextra","description":"","publisher":{"@id":"https:\/\/avextra.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/avextra.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/avextra.com\/#organization","name":"Avextra Pharma GmbH","url":"https:\/\/avextra.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/avextra.com\/#\/schema\/logo\/image\/","url":"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg","contentUrl":"https:\/\/avextra.com\/wp-content\/uploads\/2022\/08\/AVX-Logo_Wortmarke-Balken_extrablue.svg","caption":"Avextra Pharma GmbH"},"image":{"@id":"https:\/\/avextra.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.linkedin.com\/company\/avextra-ag\/","https:\/\/www.xing.com\/pages\/avextra"]},{"@type":"Person","@id":"https:\/\/avextra.com\/#\/schema\/person\/aa74df4160383edd63d06428edfecd0b","name":"Torsten Meyer-Bautor","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/avextra.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b9ef8b21e6c420b5e45a3e65c39ed5b9?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b9ef8b21e6c420b5e45a3e65c39ed5b9?s=96&d=mm&r=g","caption":"Torsten Meyer-Bautor"}}]}},"author_meta":{"display_name":"Torsten Meyer-Bautor","author_link":"https:\/\/avextra.com\/en\/author\/tmeyer-bautor\/"},"featured_img":"https:\/\/avextra.com\/wp-content\/uploads\/2024\/10\/Neurobis_Website-Vorschaubild_2048x1370-1-241008-300x201.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/avextra.com\/en\/category\/english\/\" class=\"advgb-post-tax-term\">english<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">english<\/span>"]}},"comment_count":0,"relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on 8. October 2024","modified":"Updated on 8. October 2024"},"absolute_dates_time":{"created":"Posted on 8. October 2024 13:32","modified":"Updated on 8. October 2024 13:56"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/posts\/4766"}],"collection":[{"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/comments?post=4766"}],"version-history":[{"count":5,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/posts\/4766\/revisions"}],"predecessor-version":[{"id":4775,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/posts\/4766\/revisions\/4775"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/media\/4768"}],"wp:attachment":[{"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/media?parent=4766"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/categories?post=4766"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/avextra.com\/en\/wp-json\/wp\/v2\/tags?post=4766"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}